



Long-Term Effects of Systemic Therapies on Cancer Patients

Guest Editor:

Dr. Andrew G. Robinson

Departments of Oncology,
Queen's University, Kingston, ON
K7L 5P9, Canada

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editor

Dear Colleagues,

Chemotherapy and hormonal therapy have been the cornerstone of systemic therapy for cancer patients for the past 70 years, while, more recently, targeted therapy, monoclonal antibody therapy, and immunotherapy have seen significant increases in use. Given the increasing incidence of cancer, the changing age demographics of the affected population, the increased indications for therapies in earlier stages of disease, and the increased efficacy of recent therapies, there is a growing number of long-term survivors who have been treated with systemic chemotherapy, immunotherapy, hormonal therapy, and targeted therapy. This Special Issue focuses on the long-term effects of these therapies that require special attention in cancer survivors.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.**

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Current Oncology Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/currenocol
currentoncology@mdpi.com
[X@CurrentOncology](https://twitter.com/CurrentOncology)